Howard Smith’s urologist told him his prostate cancer was not the kind you die with: “It’s the one that’s going to kill you.” ...

Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated ...

It seems we cannot go a week without hearing about some new health or beauty craze, usually on social media sites that cater ...

When you cannot get a doctor to write a prescription for the latest weight-loss injection, you probably end up on Reddit.

Local law enforcement officials are asking motorists to be more alerts on the road following a rash of crashes involving ...

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in ...

Leclaza-first regimen cuts skin side effects in Korea without losing efficacy Starting Leclaza before Rybrevant linked to ...

New late-breaking data to be presented today by the Australian and New Zealand Urogenital and Prostate (ANZUP) Clinical ...

Hello everyone. I'm Rin.Up until now, I have written about my history with Patulous Eustachian Tube (PET) and the ...

The IIM market is projected to grow at a CAGR of ~20% during 2026-2036. According to DelveInsight's analysis, the total diagnosed prevalent cases of IIM in the 7MM were approximately 200,000 cases in ...

Rawalpindi - A water tanker here on Saturday morning crushed a couple and their one-and-a-half-year old son to death after hitting their bike in ...

Xencor chose an XmAb819 dose after five of 11 patients responded; severe treatment-related events affected 72.1 per cent ...